JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Home・Akcijų sąrašas・Sanofi

Sanofi

Uždarymo kaina

43.37 0.18

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

43.08

Max

43.52

Pagrindiniai rodikliai
By Trading Economics
Pajamos	2.4B 1.6B
Pardavimai	-961M 11B
P/E Sektoriaus vid.	19.885 67.147
Pelnas, tenkantis vienai akcijai	1.102
Pelno marža	14.354
Darbuotojai	74,846
EBITDA	-1.1B 2.7B

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	+22.26% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-11B 104B
Ankstesnė atidarymo kaina	43.19
Ankstesnė uždarymo kaina	43.37

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

51.665 / 52.38 Palaikymas ir pasipriešinimas

Sanofi Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-23 06:12; UTC

Uždarbis

Sanofi Posts Higher Sales Amid Leadership Transition

2026-02-12 12:40; UTC

Pagrindinės rinkos jėgos

Sanofi Shares Fall After CEO Change

2026-01-29 11:35; UTC

Uždarbis

Sanofi Remains Committed to Vaccines After Mixed Year for Drug Pipeline -- Update

2026-04-29 12:01; UTC

Uždarbis

Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com

2026-04-27 09:32; UTC

Rinkos pokalbiai

Uždarbis

Sanofi's Dupixent Sales Growth Set to Moderate -- Market Talk

2026-04-27 09:19; UTC

Rinkos pokalbiai

Sanofi's New CEO Needs to Be Clear on Strategy -- Market Talk

2026-04-23 05:34; UTC

Uždarbis

Sanofi: 2026 Expectations Are at Constant Exchange Rates

2026-04-23 05:34; UTC

Uždarbis

Sanofi Sees Business EPS Growth Slightly Faster Than Sales in 2026

2026-04-23 05:34; UTC

Uždarbis

Sanofi Sees Sales Growth by a High Single-Digit Percentage in 2026

2026-04-23 05:34; UTC

Uždarbis

Sanofi Backs 2026 View

2026-04-23 05:33; UTC

Uždarbis

Sanofi 1Q Business Net Pft EUR2.26B

2026-04-23 05:33; UTC

Uždarbis

Analysts Saw Sanofi 1Q Business Oper Pft at EUR2.85B

2026-04-23 05:33; UTC

Uždarbis

Sanofi 1Q Business Oper Pft EUR2.97B

2026-04-23 05:32; UTC

Uždarbis

Analysts Saw Sanofi 1Q Net Sales at EUR10.22B

2026-04-23 05:32; UTC

Uždarbis

Sanofi 1Q Net Sales Rose 14% on Year at Constant Exchange Rates

2026-04-23 05:31; UTC

Uždarbis

Sanofi 1Q Net Sales EUR10.51B

2026-04-10 11:12; UTC

Rinkos pokalbiai

Sanofi Investors Might Have to Wait for Update on Strategy -- Market Talk

2026-04-10 10:54; UTC

Rinkos pokalbiai

Sanofi Could Get Boost From Dupixent U.S. Price -- Market Talk

2026-03-30 10:40; UTC

Rinkos pokalbiai

Sanofi Shares Fall After Company Reports Second Cancer Case in Trial -- Market Talk

2026-03-27 10:40; UTC

Rinkos pokalbiai

AstraZeneca Hits Goal in Lung Disease Where Rivals Missed -- Market Talk

2026-03-11 11:02; UTC

Rinkos pokalbiai

Sanofi, Regeneron's Eczema Drug Might Face Competition From Pfizer -- Market Talk

2026-02-24 14:00; UTC

Įsigijimai, susijungimai, perėmimai

This Small-Cap Biotech Stock Is Soaring 35% on Excitement Over Its Prostate Cancer Drug -- Barrons.com

2026-02-13 08:21; UTC

Rinkos pokalbiai

Sanofi's CEO Change Adds to Near-Term Uncertainty -- Market Talk

2026-02-12 15:20; UTC

Uždarbis

Sanofi Shares Fall After CEO Change -- Update

2026-02-10 14:07; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi Set Out $2.2 Bln Cash Deal for Dynavax Late Last Year

2026-02-10 14:06; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: Acquisition Includes Dynavax's Hepatitis B Vaccine, Shingles Vaccine Candidate

2026-02-10 14:05; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi Completes Acquisition of Dynavax

2026-02-10 14:00; UTC

Įsigijimai, susijungimai, perėmimai

Press Release: Sanofi Completes The Acquisition Of Dynavax >SAN.FR

2026-02-06 12:35; UTC

Uždarbis

Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio. -- Barrons.com

2026-01-29 13:00; UTC

Rinkos pokalbiai

Uždarbis

Sanofi Results Encourage, But Pipeline Strategy Should Take Priority -- Market Talk

Akcijų palyginimas

Kainos pokytis

Sanofi Prognozė

Kainos tikslas

By TipRanks

22.26% į viršų

12 mėnesių prognozė

Vidutinis 53 USD 22.26%

Aukščiausias 57 USD

Žemiausias 50 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sanofi kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

3 ratings

Pirkti

Laikyti

Parduoti

Remiantis 3 analitikų, pateikusių Sanofi akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

51.665 / 52.38Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.